In conclusion, these results indicated a strong association between SLC3A2 and progression in both NPC and HNSC, suggesting it as a promising biomarker for predicting adverse prognosis in NPC and HNSC patients. This evidence concerns the gene SLC3A2 and nasopharyngeal carcinoma.